Welcome to our dedicated page for Pfizer SEC filings (Ticker: PFE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pfizer Inc. filings document the financial, governance, capital-structure, and material-event disclosures of a global biopharmaceutical company. The company's 8-K reports include quarterly operating results, financial guidance updates, Regulation FD disclosures, clinical or regulatory disclosure categories, material agreements, and other corporate events tied to its medicines, vaccines, pipeline, and commercial organization.
Pfizer's proxy and annual-meeting filings cover board elections, auditor ratification, executive compensation, shareholder voting results, and equity-plan governance. Its capital markets filings and 8-K exhibits also disclose common stock, NYSE-listed notes, shelf registration activity, public debt offerings, note maturities, and related capital-structure terms.
Pfizer Inc. (PFE) insider activity: Chairman & CEO and Director Albert Bourla reported the acquisition of 24 phantom stock units on 10/31/2025 under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan.
The filing lists a price of $24.65 for the derivative security and shows 731,108 derivative securities beneficially owned following the transaction, held as direct ownership. These phantom stock units represent the value of one share each and are settled in cash after the reporting person’s separation from service; they may be moved into an alternative investment account at any time.
Pfizer (PFE) reported an insider transaction by Chairman & CEO and Director Albert Bourla on 10/15/2025. The filing shows the acquisition of 25 phantom stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan at a price of $24.39 per unit. Following this transaction, Bourla’s derivative holdings total 731,111 phantom stock units, held directly. Each unit represents one phantom share of common stock and will be settled in cash after separation from service; units may be transferred into an alternative investment account at any time.
Pfizer Inc. (PFE) Chairman & CEO Albert Bourla reported acquiring 83 phantom stock units on 10/14/2025 at a derivative security price of $24.52. Following this transaction, he beneficially owns 731,058 derivative securities. Each unit represents one share of common stock and was acquired under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, with settlement in cash after separation from service.
Cyrus Taraporevala, a Director of Pfizer Inc. (PFE), reported the acquisition of 1,471.743 phantom stock units on 09/30/2025. The filing shows these units represent deferred director compensation that may be settled in cash or common stock at the director's election following retirement. The units correspond to 1,471.743 underlying shares with an indicated per-share price of $25.48, and the report lists 23,444.776 shares beneficially owned by the reporting person after the transaction. The Form 4 was signed on 10/02/2025 by an attorney-in-fact, Shanice A. Reid.
Joseph J. Echevarria, a Director of Pfizer Inc. (PFE), reported an acquisition on 09/30/2025 of 1,815.149 phantom stock units that represent deferred director compensation. The filing shows these units were recorded as acquired with a per-share reference price of $25.48 and that 1,815.149 underlying common shares correspond to the units.
The form states these phantom units are deferred compensation that will be settled in cash or common stock at the director's election following the reporting person’s retirement from the Board. After the reported transaction the filing lists 144,989.542 common shares as beneficially owned. The form was signed by an attorney on behalf of Mr. Echevarria on 10/02/2025.
Albert Bourla, Pfizer's Chairman & CEO and a director, reported a transaction dated 09/15/2025 on a Form 4. He acquired 25 phantom stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan; each unit represents one phantom share and is settled in cash following separation from service. The report shows the units are tied to 25 underlying common shares at a reference price of $23.97. Following the reported transaction, the filing shows 730,907 shares beneficially owned in a direct form. The Form 4 was signed on behalf of Mr. Bourla by power of attorney on 09/17/2025.
Albert Bourla, Pfizer's Chairman & CEO and a director, reported a transaction dated 09/15/2025 on a Form 4. He acquired 25 phantom stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan; each unit represents one phantom share and is settled in cash following separation from service. The report shows the units are tied to 25 underlying common shares at a reference price of $23.97. Following the reported transaction, the filing shows 730,907 shares beneficially owned in a direct form. The Form 4 was signed on behalf of Mr. Bourla by power of attorney on 09/17/2025.
Albert Bourla, Chairman & CEO of Pfizer Inc. (PFE), acquired 24 phantom stock units on 08/29/2025 under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan. Each unit represents one phantom share of common stock and these units are settled in cash upon the reporting persons separation from service or may be transferred into an alternative investment account at any time. The filing shows a transaction price of $24.76 per unit and reports 730,806 shares beneficially owned following the transaction. The Form 4 was signed on 09/03/2025 by counsel Shanice A. Reid on behalf of Mr. Bourla.
Albert Bourla, Pfizer Inc. Chairman & CEO, acquired 24 phantom stock units on 08/15/2025. Each unit represents one phantom share of common stock and the units were granted under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan. The units are settled in cash following the reporting person's separation from service and may be transferred into an alternative investment account at any time. Following the reported transaction, the reporting person beneficially owns 730,477 shares (direct).
Pfizer Inc filed a Form 13F reporting institutional holdings, listing 24 reported positions with an aggregate market value of $576,193,012. The filing was signed by Madelyn D. Purcell on 08-11-2025 and indicates no other managers are included.